Early onset ataxia (EOA) concerns a group of rare, predominantly genetic and metabolic ataxic disorders, manifesting before the 25th year of life. [1] [2] [3] This diagnostic group covers a wide heterogeneity of disorders regarding age at onset, inheritance, and underlying pathogenesis. Consequently, the phenotype is also heterogeneous, involving both EOA with core ataxia (i.e. EOA with ataxia as the core symptom) and EOA with comorbid ataxia (i.e. EOA with other movement disorder features that may prevail over ataxia). 4 Especially in children, EOA is often prevalent as a combined phenotype, with concurrent features of dystonia, myoclonus, chorea, and spasticity, which may prevail over ataxia. 4, 5 This heterogeneity makes uniform phenotypic EOA assessment a challenging task for paediatric movement disorder specialists. Therefore, quantitative ataxia rating scales (ARS) are often used as additionally reproducible 'surrogate' biomarkers for ataxia. [5] [6] [7] [8] [9] [10] [11] The International Cooperative Ataxia Rating Scale (ICARS), 6 the Scale for Assessment and Rating of Ataxia (SARA), 7 and the Brief Ataxia Rating Scale (BARS) 8 are the most commonly applied ARS in children and adults. These ARS quantify ataxia in four domains: (1) posture and gait; (2) kinetic function; (3) speech; and (4) oculomotor function (exclusively BARS and ICARS). [6] [7] [8] ICARS is considered to be the most detailed, BARS the briefest, and SARA the most uniformly reproducible scale. [6] [7] [8] 10, 11 In children, we have shown that ARS are not only influenced by ataxia, but also by age 12 and by muscle weakness (in Friedreich's ataxia). 13 In EOA, this implies that other influences, such as concurrent movement disorders, could influence the scores. For reliable interpretation of ARS as 'ataxia' biomarkers, we therefore reasoned that, first, clarification was required of the paediatric ARS test construct. In the present EOA study, we thus aimed to elucidate ARS for: (1) observer agreement and (2) discriminant validity (i.e. the potential to determine 'ataxia severity' and not the severity of other, with ataxia concurrent movement disorders). Such information may support reliable data entry in international EOA databases, and may also support the interpretation of ARS outcomes in therapeutic trials. Especially in regards to ongoing, innovative trials in heterogeneous patients with EOA, we reasoned that confounding effects should be identified before small fluctuations in ARS scores are over-interpreted as therapeutic 'ataxic' improvement. [12] [13] [14] [15] [16] [17] Thus, we aimed to investigate the observer agreement and discriminant validity of ARS in patients with EOA.
METHOD Patients
The medical ethical committee of the University Medical Center Groningen, the Netherlands, approved the study. We based our sample size calculation on previously published interobserver agreement (intraclass correlation coefficient [ICC] ) data in adults with ataxia, 7 because data on quantitative ARS scores in children with ataxia are still lacking. In adults with ataxia, a sample size of 36 patients scored by three observers achieved a 90% power (b=0.1) to detect an ICC of 0.8 or over the null hypothesis of a moderate ICC of 0.6, using a significance level of 0.05. Based on the clinical diagnosis (patient record descriptions from 1998 to 2012), we approached 40 patients (28 males, 12 females; mean age 15y 3mo [range 5-34y]). All patients were clinically identified with ataxic features before the 25th year of life and fulfilled the 'classical' definition of EOA. 1 We excluded patients with postnatally acquired focal cerebellar lesions (such as by infections, trauma, inflammation, or cerebrovascular attacks). In accordance with Dutch medical ethical law, legal representatives (when younger than 18y of age) and patients (when older than 12y of age) consented to participate. The response rate was 100%. For clinical description of the included patients, see Table I .
Procedure
We videorecorded ARS performances in all 40 patients. 12 Three paediatric neurologists (RB, RJL, DAS) quantitatively scored the videotaped test-performances according to the guidelines of ICARS, SARA, and BARS. We determined interobserver agreement by comparing the total and subscale scores of the three assessors. After a latent time interval of 5 (3-7) weeks, the three assessors repeated their ARS assessments in the first 10 videotaped patients, without permission to review their previous scores. We determined intraobserver agreement by comparing the first and second scores. After a latent time interval of 6 months, the same assessors phenotyped the video-taped testperformances for the presence of ataxia and/or other movement disorders (i.e. ataxia, dystonia, chorea, myoclonus, tremor, spasticity, and 'sloppiness'), either as the primary or as the secondary feature. We subsequently assigned patients to an EOA subgroup with 'core ataxia' when (1) all three assessors independently recognized ataxia as the primary movement disorder, or when (2) all three assessors had independently confirmed the presence of ataxia and when the underlying diagnosis (genetically and/or metabolically) confirmed an ataxic phenotype. We assigned patients to an EOA subgroup with 'comorbid ataxia' when the criteria for the EOA subgroup 'core ataxia' were not met and when ataxia was observed (by at least one observer) as a concurrent feature with other movement disorders.
The assessors indicated the perceived severity of the movement disorder (i.e. mild [1] , moderate [2] , or severe [3] ). To check for the reliability of these assessments, we compared the perceived severity between the participating assessors and four other members of the movement disorder team of the University Medical Center Groningen (who had not rated the ARS), revealing a significant association (v 2 test; p<0.001). 5 For global data interpretation of phenotypic ataxia severity assessment, we also compared phenotypic ataxia severity outcomes with the ataxia severity grading system, proposed by Klockgether et al. 18 (i.e. stage 18 Underlying diagnoses in the primary-EOA subgroup were: Friedreich's ataxia (n=7), Niemann-Pick type C (n=1), ataxia with vitamin E deficiency (n=3), NARP-mutation (n=1), ataxia telangiectasia (n=1), Kearns-Sayre syndrome (n=1), North Sea myoclonus (GOSR2-mutation) (n=4), 2-methyl-3-hydroxybutyryl-CoA-hydrogenase deficiency (MHBD) (n=1), Joubert syndrome (KIAA0586 mutation) (n=1), CACNA1A mutation (n=1), and unknown causes (n=5). Underlying diagnoses in the combined-EOA subgroup were: benign hereditary chorea (TIFF1 mutation) (n=1), Huntington disease (n=1), cerebellar malformation (n=1), Chediak-Higashi syndrome (n=1), spastic paraplegia type 11 (SPG-11 mutation) (n=1), CTNNB1 mutation (n=1), ataxic cerebral palsy (n=1), congenital CMV infection (n=1), functional disorder (n=1), spinocerebellar ataxia type 29 (n=2), and unknown causes (n=1). EOA, early onset ataxia; CI, confidence interval; ICARS, International Cooperative Ataxia Rating Scale; SARA, Scale for Assessment and Rating of Ataxia; BARS, Brief Ataxia Rating Scale.
What this paper adds
• Ataxia rating scales (ARS) are reliable in assessing early onset ataxia (EOA).
• Discriminant validity of ARS is low.
• ARS scores should be interpreted in homogeneous EOA phenotypes. 0, no gait difficulties; stage 1, gait difficulties; stage 2, loss of independent gait with permanent use of a walking aid; stage 3, confinement to a wheelchair; stage 4, dead).
Statistical analysis
We performed statistical analysis by PASW Statistics 20 for Windows (SPSS, Hong Kong). We determined mean ICARS, SARA, and BARS total scores from the quantitative assessments by the three assessors. We also determined ARS total scores per primary movement disorder and median phenotypic severity of the primary movement disorder by the three assessors. We assessed normality of age, disease duration, and ARS total scores, by probability plots (Q-Q plots). We compared the ARS scores between patients with EOA with core ataxia and patients with EOA with comorbid ataxia by Student's t-test (in case of nonnormality by Mann-Whitney U test).
We calculated the percentage of the subscale score compared with the total score by: subscale score/total ARS score9100%. We compared outcomes between both EOA subgroups.
We determined interobserver and intraobserver agreement by ICC. We used the two-way random single measurement variant for the interobserver agreement and the one-way single measurement variant for the intraobserver agreement. 19 According to Cicchetti, 20 We determined the correlation between the ARS outcomes by Pearson coefficient (in case of non-normality we used Spearman's rho coefficient). We determined the correlation between the ataxia severity grading system proposed by Klockgether et al. 18 and the phenotypic severity of the movement disorder, and we also correlated outcomes with total ARS scores by Spearman's rho coefficient. In perspective of previously reported ARS age-dependency in healthy children, we compared the paediatric EOA scores with these historic age-related mean control values, by MannWhitney U test. 12 To determine the discriminant validity of ARS for ataxia severity, we determined the association between the primary movement disorder features (i.e. ataxia, dystonia, myoclonus, chorea, spasticity, tremor, and 'sloppiness') and the total ARS scores by the KruskallWallis test. We performed a multiple regression analysis to determine the effect of age, sex, disease duration, primary movement disorder feature, and the severity of the primary movement disorder feature on the total ARS scores. Because ARS are specifically designed to reflect ataxia severity, we deliberately included semi-quantitative information about the perceived phenotypic severity of the most dominant movement disorder (including other movement disorders then ataxia) in our model. We applied a stepwise regression analysis with forward selection starting with age, 12 and we explored which variables would have added predictive value over and above variables already in the model. 22 All statistical tests were two-tailed. Statistical significance was set at p<0.05.
RESULTS

Patient characteristics
There were no missing data. In two of the 40 included patients, none of the assessors recognized ataxia as part of the movement disorder. These two patients (diagnosed with DYT-6 and SPG-11) were therefore excluded from further analysis. Thus, the EOA data were obtained from the remaining 38 patients. Subdivision into EOA subgroups with core ataxia and comorbid ataxia revealed 26 (68.4%) patients in the former group and 12 (32.6%) patients in the latter group. For patient characteristics, see Table I . Probability plots revealed normally distributed disease duration. Age and the total ARS scores (ICARS, SARA, and BARS) were not normally distributed. Comparing age (16y 11mo vs 12y) and disease duration (12y 1mo vs 7y 6mo) between EOA with core ataxia and EOA with comorbid ataxia revealed no significant difference (p=0.112 and p=0.096 respectively). Comparing the ataxia severity grading system proposed by Klockgether et al. 18 between the EOA subgroups revealed no significant difference (p=0.436). However, comparing the phenotypic movement disorder severity grading system between the EOA subgroups revealed higher movement disorder severity in the EOA subgroup with core ataxia than in the EOA subgroup with comorbid ataxia (p=0.040). Total ICARS, SARA, and BARS scores were significantly higher in EOA with core ataxia than in EOA with comorbid ataxia (p=0.001 for ICARS, SARA, and BARS, see Table I ).
In 21 out of 26 (80.7%) patients with EOA with core ataxia, all three assessors recognized ataxia as the primary movement disorder feature. The remaining 5 out of 26 (19.3%) patients with EOA were assigned to the core ataxia subgroup by the underlying genetic or metabolic diagnosis (AVED n=2; GOSR2 mutation n=3). In all of these five patients, two of the three assessors recognized ataxia as the primary movement disorder feature, and one assessor recognized ataxia as a secondary movement disorder feature. Total ARS scores were similar between the two EOA core ataxia subgroups (i.e. either identification by all three assessors, or identification by two assessors and the underlying diagnosis [p=0.753, p=0.659, and p=0.613 for ICARS, SARA, and BARS respectively]).
ARS subscales in patients with EOA
ARS subscale scores were not significantly different between EOA subgroups with core ataxia and comorbid ataxia (Table SI, online supplementary information).
Reliability of ARS in patients with EOA
The quantitative ARS scores were characterized by an interobserver agreement (ICC) of 0.969, 0.977, and 0.913 (for ICARS, SARA, and BARS respectively; all p<0.001, i.e. excellent and almost perfect, according to Cicchetti 
Discriminant validity of ARS in patients with EOA
All three ARS were strongly correlated (r s 0.988, 0.958, and 0.941 for ICARS and SARA, ICARS and BARS, SARA and BARS respectively [all p<0.001]). The ataxia severity grading system proposed by Klockgether et al. 18 was moderately correlated (r s 0.450-0.476, p<0.001) and the phenotypic movement disorder severity grading system was strongly correlated (r s 0.775-0.801, p<0.001) with total ARS scores. The ataxia severity grading system proposed by Klockgether et al. 18 and the phenotypic movement disorder severity grading system were also significantly correlated with each other (r s 0.513; p=0.001). Comparing quantitative ARS scores between included children with EOA (<18y of age; n=25) and historic age-related mean control values, 12 revealed significantly higher ARS scores in the children with EOA (p<0.001 for ICARS, SARA, and BARS, Fig. 1 ).
Phenotypic assessment of the primary movement disorder feature revealed 27 patients with ataxia (27 out Fig. 2 ).
Multiple regression analysis showed that total ARS scores are significantly predicted by the severity of the primary movement disorder in ICARS (b=0.86; p=0.026), SARA (b=0.83; p=0.026), and BARS (b=0.88; p=0.024), independent of whether the primary movement disorder features concern ataxia or not. The severity of the prevailing movement disorder explained a significant proportion in the variance of the ARS scores for ICARS (R 2 =0.764; p<0.001), SARA (R 2 =0.775; p<0.001), and BARS (R 2 =0.754; p<0.001). The type of primary movement disorder did not render a significant F-change, nor did age, sex, or disease duration, implicating that these variables could be omitted from our regression model (for further analysis, see Table SIII , online supporting information).
DISCUSSION
In patients with EOA, ICARS, SARA, and BARS reveal high interobserver and intraobserver agreement, reflecting the reliability of the scores. However, the discriminant validity of ARS failed to discern between the influence of ataxia and the influence of other movement disorders. In EOA with the phenotype core ataxia, ARS can thus be regarded as reliable and reproducible biomarkers for ataxia severity. However, in children with EOA with the phenotype comorbid ataxia, ARS scores can be confounded by the influence of other concurrent movement disorders. This implies that ARS scores do not necessarily reflect the severity of 'ataxia' alone.
In patients with EOA, total ARS scores revealed similarly high ICC outcomes for interobserver and intraobserver agreement, as previously reported in adults with ataxia (0.91-0.99 vs 0.91-0.98 respectively). [6] [7] [8] [9] [10] [11] This implies that the total scores of all three ARS are highly reproducible and that one may choose a scale for its own intrinsic properties, instead of for reasons of interobserver agreement, alone. However, subscale analysis reveals relatively low interobserver agreement for the oculomotor subscale. As oculomotor parameters are not included in the SARA, SARA might be preferred above other ARS; 7 but, this would only be valid under the premise that information on oculomotor function could be intentionally left out.
Although previously published ICC results in healthy children (0.62-0.96) 12 appear lower than the present data in children with EOA, this does not necessarily imply that the reproducibility in healthy children is lower. This is explained by the method of ICC calculation, in which a small variation in (healthy age-related) scores will mathematically induce a low numerical ICC outcome, whereas the absolute observer differences can be the same. This implicates that the numerical ICC value is not necessarily indicative of the score agreeability alone.
Interestingly, we observed that cross-sectional EOA ARS scores were not significantly predicted by age. This is understandable as the severity of the primary movement disorder exerted a much stronger effect on the EOA ARS scores than did age (i.e. >87% more). Despite this, consideration of ARS age-dependency is advisory, especially when longitudinal ARS scores with minimal changes (cut-off margins) are being considered as relevant for therapeutic gain. 23, 24 Regarding discriminant validity, multiple regression analysis revealed that the severity of the primary movement disorder influenced ARS scores, independent of the phenotype of the primary movement disorder. In the EOA subgroup with core ataxia, ARS outcomes were thus reflective of ataxia severity. However, in the EOA subgroup with comorbid ataxia, ARS scores were confounded by the influence of other concurrent movement disorders. In addition to previously described confounding factors (such as paediatric age and muscle strength in patients with Friedreich's ataxia), 12, 13 one might anticipate that additional influences, such as neuropathy, could also confound ARS scores. As different patient groups are needed to substantiate this hypothesis, we hope that future studies will elucidate this point.
Overall, the insight provided into the ARS construct has direct implications for the assessment of therapeutic interventions in children with EOA. 23, 24 When small changes in ARS scores are being considered as indicators for 'therapeutic' ataxia improvement, one should strive to include homogeneous patients (regarding both age and phenotype). 16, 17 There are some weaknesses in this study. First, patients were quantitatively scored and phenotyped by the same assessors. However, because there was a time interval (of 6mo) between both assessments, and because assessors were not allowed to review their previous scores, a bias appears unlikely. Second, in the absence of quantitative ARS data in children with EOA, our sample size calculation was based on ARS ICC data in adults with ataxia. 7 We are aware of the potential limitation on quantitative ARS data by the relatively small sample size, especially regarding the applied multiple regression analysis. However, because the underlying disorders of the included patients with EOA are rare, we suggest that these data can be interpreted as indicative. We hope that future international studies will have larger sample sizes to allow elucidation of these findings to further extent. Third, we are aware that the Friedreich Ataxia Rating Scale was not included in the present analysis. However, because SARA was recently characterized as a reliable scale in patients with Friedrich's ataxia, 25 and because SARA is scores do not significantly differ between primary ataxia and other primary movement disorder (p=0.062; p=0.068, and p=0.072 for ICARS, SARA, and BARS respectively). *26 out of 27 patients with ataxia as median primary movement disorder also fulfilled the criteria for EOA with core ataxia. In one patient unfulfilling the criteria for EOA with core ataxia, ataxia was recognized by two of three assessors as the primary movement disorder. ICARS, International Cooperative Ataxia Rating Scale; SARA, Scale for Assessment and Rating of Ataxia; BARS, Brief Ataxia Rating Scale.
highly correlated with ICARS and BARS, one may deduce that ICARS, SARA, and BARS are applicable in all patients of the EOA group, including Friedreich's ataxia. To conclude, ARS are reliably reproducible in patients with EOA. In patients with EOA with a core ataxic phenotype, total ICARS, SARA, and BARS scores can be regarded as sufficiently reliable for assessment of the ataxia severity. However, in patients with EOA with a comorbid ataxic phenotype, ARS are not only influenced by ataxia, but also by other concurrent movement disorders. Despite high reliability of ARS scores, discriminant validity appears insufficient for phenotypic EOA subgroups with comorbid ataxia. For reliable data interpretation of ARS scores, we conclude that the scores should be interpreted in homogeneous phenotypic EOA groups.
SUPPORTING INFORMATION
The following additional material may be found online: Table SI : Percentage (%) of ataxia rating scale (ARS) subscale scores in early onset ataxia (EOA) subgroups with core ataxia and comorbid ataxia. 
